Ovid Therapeutics Inc. (OVID) stock
Close on Nov 11, 2026Market cap $542.93MP/E –Yield –
Ovid Therapeutics Inc. saw revenue fall 78.0% to $1.45M over the twelve months to Sep 30, 2026. Free cash flow was -$38.33M. At the latest close the market valued the company at $542.93M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $542.93M
- P/E ratio
- –
- Price to sales
- 374.18
- Price to book
- 2.73
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.45M
- Net income
- -$43.11M
- Free cash flow
- -$38.33M
Trading
- Next earnings
- Mar 17, 2027 (estimated, before the open)
- Previous close
- $2.80
- Open
- $2.80
- Day's range
- $2.66 – $2.86
- Volume
- 1,823,066
- Average volume (20 days)
- 2,477,228
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.24
- 52-week range
- $1.18 – $3.10
- RSI (14 days)
- 59.4
- Volatility (1 year)
- 77.3%
- Relative volume
- 1.01×
- WACC
- 11.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OVID | S&P 500 | Difference | OVID per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.0% | -2.4% | +15.4 pts | ||
| 3 months | +7.8% | -1.2% | +8.9 pts | ||
| Year to date | +70.6% | +12.3% | +58.3 pts | ||
| 1 year | +105.9% | +12.4% | +93.5 pts | ||
| 3 years | -14.5% | +78.8% | −93.3 pts | -5.1% | +21.4% |
| 5 years | -20.8% | +75.2% | −96.0 pts | -4.6% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ovid Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- News
- News
About Ovid Therapeutics
Pharmaceutical Preparations
Ovid is a biopharmaceutical company that develops small molecule medicines to treat central nervous system disorders. The company focuses on addressing conditions characterized by neuronal hyperexcitability, including rare epilepsies and psychiatric disorders. Its primary clinical-stage programs include OV329, a GABA-aminotransferase inhibitor evaluated for focal onset seizures, tuberous sclerosis complex, and infantile spasms, alongside a library of potassium-chloride cotransporter 2 direct activators, led by the oral candidate OV4071. Its targeted patient populations comprise individuals suffering from drug-resistant seizures, schizophrenia, and psychoses associated with Parkinson's disease and Lewy body dementia.
Company profile, executives and historyOvid Therapeutics stock: common questions
What is Ovid Therapeutics's stock price?
OVID closed at $2.78 on Nov 11, 2026, down 0.71% on the day. Over the past 52 weeks it traded between $1.18 and $3.10.
What is Ovid Therapeutics's market cap?
Ovid Therapeutics was worth $542.93M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Ovid Therapeutics make?
Ovid Therapeutics reported revenue of $1.45M for the twelve months to Sep 30, 2026, down 78.0% from a year earlier.
Does Ovid Therapeutics pay a dividend?
No. Ovid Therapeutics has not paid a cash dividend over the last twelve months.
When does Ovid Therapeutics report earnings next?
Ovid Therapeutics is expected to report Q4 FY2026 results on Mar 17, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has OVID stock performed over the past year?
Including dividends, OVID returned +105.9% over the past year, against +12.4% for the S&P 500.
How many OVID shares are sold short?
18M shares were sold short at the latest FINRA report, 10.75% of the float, or 8.2 days of average trading volume.
Who are Ovid Therapeutics's competitors?
Companies most similar to Ovid Therapeutics by business, industry and size include KRSA, ATXI, XENE, LPCN, PRAX.
See a number that looks wrong?